What Are the Prospects for Inovio's COVID Vaccine?
Inovio Pharmaceuticals (NASDAQ: INO) is one of several companies that lag behind the leaders in the COVID-19 vaccine race. The biotech is currently evaluating its COVID-19 vaccine candidate INO-4800 in a phase 2 study. In this Motley Fool Live video recorded on March 3, 2021, Fool.com contributors Keith Speights and Brian Orelli discuss what the prospects for Inovio's COVID vaccine might be.
Source Fool.com